Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.
Stijn Muselaers, Selcuk Erdem, Riccardo Bertolo, Alexandre Ingels, Önder Kara, Nicola Pavan, et al. (2022). PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. JOURNAL OF CLINICAL MEDICINE, 11/2022(7), 1-11 [10.3390/jcm11071829].
PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature
Nicola Pavan;
2022-03-25
Abstract
Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jcm-11-01829-v2.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
245.11 kB
Formato
Adobe PDF
|
245.11 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
